Generic Benchmarking: Brand Erosion at Patent Expiry

Table of Contents

EXECUTIVE SUMMARY

• Scope of the report
• Key findings

OVERVIEW OF BRAND EROSION IN THE SEVEN MAJOR MARKETS

• Analysis of brand sales and volume erosion in the seven major markets
• Erosion of standard oral and parenteral formulations at patent expiry in the seven major markets
  • Brand erosion in the US market
  • Brand erosion in the UK
  • Brand erosion in Germany
  • Brand erosion in France
  • Brand erosion in Spain
  • Brand erosion in Italy
  • Brand erosion in Japan
• Top 10 most eroded brands
  • Omnicef (cefdinir, Abbott)
  • Lamisil (terbinafine, Novartis)
  • Zofran (ondansetron, GlaxoSmithKline)
  • Zyrtec (cetirizine, Pfizer)
  • Camptosar (irinotecan, Pfizer)
  • Mobic (meloxicam, Boehringer Ingelheim)
  • Coreg (carvedilol, GlaxoSmithKline)
  • Kytril (granisetron, Roche)
  • Cerebyx (fosphenytoin, Eisai)

OVERVIEW OF PRICE OF GENERICS VERSUS ORIGINAL BRANDS

• Price of generic drugs in the seven major markets
  • Generics prices in the US
  • Generics prices in the UK
  • Generics prices in Germany
  • Generics prices in France
  • Generics prices in Italy
  • Generics prices in Spain
  • Generics prices in Japan

BRAND EROSION BY VALUE

• Brand erosion by value across the seven major markets
  • Brand erosion by value in the US
  • Brand erosion by value in the UK
  • Brand erosion by value in Germany
  • Brand erosion by value in France
  • Brand erosion by value in Italy
  • Brand erosion by value in Spain
  • Brand erosion by value in Japan

BRAND EROSION BY ATC GROUP

• Overview of ATC classification
  • Brand erosion by ATC group in the US
  • Brand erosion by ATC group in the UK
  • Brand erosion by ATC group in Germany
  • Brand erosion by ATC group in France
  • Brand erosion by ATC group in Italy
  • Brand erosion by ATC group in Spain
  • Brand erosion by ATC group in Japan

REFORMUALTIONS - EFFECTIVE PROTECTION AGAINST GENERIC EROSION?

• Overview of reformulations
  • The effect of generic defense reformulation strategies
  • Fosamax D did not incentivize enough patients to switch to the follow-on drug
  • Pravachol' s loss of sales is due to poor head-to-head studies

BIBLIOGRAPHY

• Publications and online articles
• Datamonitor resources

TABLES

• Table: Top 10 most eroded brands after 6 months of generic entry , Q2 2006 - Q2 2008

FIGURES

• Figure: Mean branded standard oral drug value ($) and volume (SU) following generic entry between Q2 2006 and Q2 2008 in the seven major markets
• Figure: Incentives for generic prescribing in the US market
• Figure: Mean branded standard oral and parenteral drug value ($) and volume (SU) following generic entry between Q2 2006 and Q2 2008 in the seven major markets
• Figure: Mean brand erosion of oral versus parenteral drugs at patent expiry between Q2 2006 and Q2 2008 in the seven major markets
• Figure: Mean branded standard oral and parenteral drug value ($) and volume (SU) following generic entry between Q2 2006 and Q2 2008 in the US market
• Figure: US sales of branded meloxicam versus generic competition from Lupin, Teva and Zydus Cadila
• Figure: Mean branded standard oral and parenteral drug value ($) and volume (SU) following generic entry between Q2 2006 and Q2 2008 in the UK
• Figure: UK sales erosion of Propecia, Proscar, the total brand erosion and generic finasteride, Q2 2006 - Q2 2008
• Figure: Mean branded standard oral and parenteral drug value ($) and volume (SU) following generic entry between Q2 2006 and Q2 2008 in Germany
• Figure: Sales erosion of Eloxatin versus generic oxaliplatin in Germany between Q2 2006 and Q2 2008
• Figure: Incentives for generic prescribing in the French market
• Figure: Mean branded standard oral and parenteral drug value ($) and volume (SU) following generic entry between Q2 2006 and Q2 2008 in France
• Figure: Sales erosion of Norvasc/Amlor and Caduet versus generic competition in France, Q2 2007 - Q2 2008
• Figure: Barriers to generic erosion of brands in Spain and Italy
• Figure: Mean branded standard oral and parenteral drug value ($) and volume (SU) following generic entry between Q2 2006 and Q2 2008 in Spain
• Figure: Sales of Kytril in its oral and parenteral formulations versus generic competition in Spain, Q2 2006 - Q2 2008
• Figure: Mean branded standard oral and parenteral drug value ($) and volume (SU) following generic entry between Q2 2006 and Q2 2008 in Italy
• Figure: Seasonal branded and generic sales erosion of cetirizine in Italy, Q2 2006 - Q2 2008
• Figure: Branded and generic sales erosion of and oxcarbazepine and zolpidem in Italy, Q2 2006 - Q2 2008
• Figure: Incentives for generic prescribing in the Japanese market
• Figure: Mean branded standard oral and parenteral drug value ($) and volume (SU) following generic entry between Q2 2006 and Q2 2008 in Japan
• Figure: Brand erosion (%) of cabergoline in Germany, Italy, UK and Japan, Q4 2006 - Q2 2008
• Figure: Mean generic price versus mean branded price of standard oral drugs, one quarter prior to generic entry in the seven major markets, Q2 2006 - Q2 2008
• Figure: Mean generic price versus mean branded price of standard parenteral drugs, one quarter prior to generic entry, Q2 2006 - Q2 2008
• Figure: Mean generic price versus mean branded price of oral and parenteral drugs in the US, one quarter prior to generic entry, Q2 2006 - Q2 2008
• Figure: Mean generic price versus mean branded price of oral and parenteral drugs in the UK, one quarter prior to generic entry, Q2 2006 - Q2 2008
• Figure: Mean generic price versus mean branded price of oral and parenteral drugs in Germany, one quarter prior to generic entry, Q2 2006 - Q2 2008
• Figure: Mean generic price versus mean branded price of oral and parenteral drugs in France, one quarter prior to generic entry, Q2 2006 - Q2 2008
• Figure: Mean generic price versus mean branded price of oral and parenteral drugs in Italy, one quarter prior to generic entry, Q2 2006 - Q2 2008
• Figure: Mean generic price versus mean branded price of oral and parenteral drugs in Spain, one quarter prior to generic entry, Q2 2006 - Q2 2008
• Figure: Generic price versus branded price of oral and parenteral drugs in Japan, one quarter prior to generic entry, Q2 2006 - Q2 2008
• Figure: Mean branded drug value ($) erosion following generic entry in the US, Q2 2006 - Q2 2008
• Figure: Branded drug value ($) erosion following generic entry in the UK, Q2 2006 - Q2 2008
• Figure: Sales of Coversyl and Coversyl Plus versus total generic perindopril sales in the UK, Q2 2006 - Q2 2008
• Figure: Branded drug value ($) erosion following generic entry in Germany, Q2 2006 - Q2 2008
• Figure: Branded drug value ($) erosion following generic entry in France, Q2 2006 - Q2 2008
• Figure: Branded drug value ($) erosion following generic entry in Italy, Q2 2006 - Q2 2008
• Figure: Branded drug value ($) erosion following generic entry in Spain, Q2 2006 - Q2 2008
• Figure: Branded drug value ($) erosion following generic entry in Japan, Q2 2006 - Q2 2008
• Figure: Mean branded erosion (%) of value ($) and volume (SU) according to ATC group following generic entry in the US between Q2 2006 and Q2 2008
• Figure: Mean branded erosion (%) of value ($) and volume (SU) according to ATC group following generic entry in the UK between Q2 2006 and Q2 2008
• Figure: Mean branded erosion (%) of value ($) and volume (SU) according to ATC group following generic entry in Germany between Q2 2006 and Q2 2008
• Figure: Mean branded erosion (%) of value ($) and volume (SU) according to ATC group following generic entry in France between Q2 2006 and Q2 2008
• Figure: Mean branded erosion (%) of value ($) and volume (SU) according to ATC group following generic entry in Italy between Q2 2006 and Q2 2008
• Figure: Mean branded erosion (%) of value ($) and volume (SU) according to ATC group following generic entry in Spain between Q2 2006 and Q2 2008
• Figure: Mean branded erosion (%) of value ($) and volume (SU) according to ATC group following generic entry in Japan between Q2 2006 and Q2 2008
• Figure: Mean branded erosion (%) of value ($) and volume (SU) for reformulated drugs - Ambien, Mavik, Focalin and Coreg, Q2 2006 - Q2 2008
• Figure: Mean brand erosion of Novartis' s Focalin (dexmethylphenidate) for its oral standard and oral extended formulations, Q2 2006 - Q2 2008
• Figure: Mean brand erosion of GlaxoSmithKline' s Coreg (carvedilol) for its oral standard and oral extended formulations, Q2 2006 - Q2 2008
• Figure: Sales of Fosamax and Fosamax Plus D versus generic alendronic acid in the US market, Q2 2006 - Q2 2008
• Figure: Sales of Pravachol and Pravigard against generic competition in France, Q2 2006 - Q2 2008
• Figure: Drugs experiencing generic erosion between Q1 2006 and Q2 2007
• Figure: Erosion curves for each drug experiencing generic entry
• Figure: Mean erosion curve for drugs A, B, and C experiencing generic entry
• Figure: Mean branded erosion of value ($) and volume (SU) for ATC group A (endocrine, metabolic and genetic disorders), Q2 2006 - Q2 2008
• Figure: Mean branded erosion of value ($) and volume (SU) for ATC group C (cardiovascular), Q2 2006 - Q2 2008
• Figure: Mean branded erosion of value ($) and volume (SU) for ATC group D (immunology and inflammation), Q2 2006 - Q2 2008
• Figure: Mean branded erosion of value ($) and volume (SU) for ATC group G (urology and gender-specific health), Q2 2006 - Q2 2008
• Figure: Mean branded erosion of value ($) and volume (SU) for ATC group J (infectious diseases), Q2 2006 - Q2 2008
• Figure: Mean branded erosion of value ($) and volume (SU) for ATC group L (oncology), Q2 2006 - Q2 2008
• Figure: Mean branded erosion of value ($) and volume (SU) for ATC group M (musculoskeletal), Q2 2006 - Q2 2008
• Figure: Mean branded erosion of value ($) and volume (SU) for ATC group N (central nervous system), Q2 2006 - Q2 2008
• Figure: Mean branded erosion of value ($) and volume (SU) for ATC group R (respiratory), Q2 2006 - Q2 2008